Medicine Wolverine

gallery 06 · the citation register

BPC-157 TB-500 references

Every claim on this site resolves to one of these — the constituent literature, the recent reviews, and the audited FDA compounding sources.

Back to the researchSee the access status

How to read this register

These are the BPC-157 TB-500 references behind every quantitative claim on the site. The list divides into three registers. References 1-8 are the foundational constituent literature — the BPC-157 tendon and pharmacokinetic work and the Thymosin Beta-4 mechanism and human-safety studies. References 9-11 are recent reviews (2025-2026) that bound the evidence honestly. References 12-14 are the audited FDA sources for the compounding and access status on the legal-status page. Each entry below carries its journal, year, DOI, and PubMed or FDA link so any claim can be traced to source.

Constituent literature

The eight foundational studies span both legs of the blend: the BPC-157 transected-Achilles-tendon result [1], the BPC-157 VEGFR2 angiogenesis mechanism [2], the Thymosin Beta-4 actin-sequestration crystal structure [3], the consolidated Thymosin Beta-4 mechanism review [4], the first formal BPC-157 pharmacokinetic/ADME characterization [5], two human Phase 1 safety studies of full-length and recombinant Thymosin Beta-4 [6][7], and the chemical synthesis that defines the TB-500 heptapeptide itself [8]. The full citations are listed in the reference register.

Recent reviews and the audited FDA sources

Three recent reviews frame the current evidence: a 2025 systematic review of BPC-157 in orthopaedic sports medicine [9], a 2026 narrative review of approved and unapproved peptides for musculoskeletal injury and athletic performance [10], and a 2025 narrative review weighing regeneration against risk for BPC-157 [11]. The regulatory entries — the FDA Category 2 safety-risks list [12], the FDA Section 503A compounding framework [13], and the FDA July 23-24, 2026 advisory-committee meeting calendar [14] — are the audited sources for the legal-status page. The full citations follow in the reference register.

  1. Staresinic M, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating muscle healing; effects on transected rat Achilles tendon and in vitro tendocyte growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Wang Y, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
  6. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. ↗
  7. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(16):7866-7875. ↗
  8. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  9. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  10. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  11. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  12. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Category 2 list entries for 'BPC-157' and 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; effective with the September 29, 2023 update to the list of bulk drug substances nominated for use under section 503A. ↗
  13. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Definitions of the Category 1 / Category 2 interim-policy framework and the 503A/503B compounding pathway. ↗
  14. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Public calendar listing BPC-157 and TB-500 among bulk drug substances 'being considered for inclusion on the 503A Bulks List' (a scheduled discussion of substances under evaluation, not a decision). ↗